SLE - a disease of clearance deficiency?

被引:164
作者
Munoz, LE
Gaipl, US
Franz, S
Sheriff, A
Voll, RE
Kalden, JR
Herrmann, M
机构
[1] Univ Erlangen Nurnberg, Dept Med 3, Inst Clin Immunol, D-91054 Erlangen, Germany
[2] Nikolaus Fiebiger Ctr Mol Med, IZKF Res Grp N2, Erlangen, Germany
关键词
apoptosis; necrosis; phagocytosis; clearance; autoimmunity; SLE;
D O I
10.1093/rheumatology/keh693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus (SLE) is a multifactorial disease and its pathogenesis and precise aetiology remain unknown. Under physiological conditions, neither apoptotic nor necrotic cell material is easily found in tissues because of its quick removal by a highly efficient scavenger system. Autoantigens are found in apoptotic and necrotic material and they are recognized by autoimmune sera from SLE patients. The clearance of dying cells is finely regulated by a highly redundant system of receptors on phagocytic cells and bridging molecules, which detect molecules specific for dying cells. Changes on apoptotic and necrotic cell surfaces are extremely important for their recognition and further disposal. Some SLE patients seem to have an impaired ability to clear such apoptotic material from tissues, and this could cause the breakdown of central and peripheral mechanisms of tolerance against self-antigens. In this article, we address the cells, receptors and molecules involved in the clearance process and show how deficiencies in this process may contribute to the aetiopathogenesis of SLE.
引用
收藏
页码:1101 / 1107
页数:7
相关论文
共 90 条
[1]   NUCLEOSOME-RESTRICTED ANTIBODIES ARE DETECTED BEFORE ANTI-DSDNA AND/OR ANTIHISTONE ANTIBODIES IN SERUM OF MRL-MP LPR/LPR AND +/+-MICE, AND ARE PRESENT IN KIDNEY ELUATES OF LUPUS MICE WITH PROTEINURIA [J].
AMOURA, Z ;
CHABRE, H ;
KOUTOUZOV, S ;
LOTTON, C ;
CABRESPINES, A ;
BACH, JF ;
JACOB, L .
ARTHRITIS AND RHEUMATISM, 1994, 37 (11) :1684-1688
[2]  
Amoura Z, 1999, ARTHRITIS RHEUM, V42, P833, DOI 10.1002/1529-0131(199905)42:5<833::AID-ANR1>3.0.CO
[3]  
2-T
[4]  
APPELT U, 2004, CELL DEATH DIFFER, V12, P12
[5]  
Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO
[6]  
2-K
[7]   Development of systemic lupus erythematosus in a patient with selective complete C1q deficiency [J].
Berkel, AI ;
Petry, F ;
Sanal, O ;
Tinaztepe, K ;
Ersoy, F ;
Bakkaloglu, A ;
Loos, M .
EUROPEAN JOURNAL OF PEDIATRICS, 1997, 156 (02) :113-115
[8]   Serum amyloid P component binds to Fcγ receptors and opsonizes particles for phagocytosis [J].
Bharadwaj, D ;
Mold, C ;
Markham, E ;
Du Clos, TW .
JOURNAL OF IMMUNOLOGY, 2001, 166 (11) :6735-6741
[9]   Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity [J].
Bickerstaff, MCM ;
Botto, M ;
Hutchinson, WL ;
Herbert, J ;
Tennent, GA ;
Bybee, A ;
Mitchell, DA ;
Cook, HT ;
Butler, PJG ;
Walport, MJ ;
Pepys, MB .
NATURE MEDICINE, 1999, 5 (06) :694-697
[10]   Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages [J].
Bijl, M ;
Horst, G ;
Bijzet, J ;
Bootsma, H ;
Limburg, PC ;
Kallenberg, CGM .
ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :248-254